{"id":14360,"date":"2016-10-17T19:13:36","date_gmt":"2016-10-17T23:13:36","guid":{"rendered":"http:\/\/goldstocksforex.com\/?p=14360"},"modified":"2016-10-17T19:13:36","modified_gmt":"2016-10-17T23:13:36","slug":"weekly-investment-commentary-from-bob-doll-nuveen","status":"publish","type":"post","link":"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/","title":{"rendered":"Weekly Investment Commentary from Bob Doll | Nuveen"},"content":{"rendered":"<p>From Bob Doll:<\/p>\n<p><strong>Equities may struggle until corporate earnings improve.<\/strong><br \/>\nFor the past 18 months, equities have been able to make modest gains despite declining corporate profits. This has largely been due to highly accommodative monetary policy and central banks\u2019 willingness to engage in new easing measures. Additionally, investors have been willing to look past the earnings recession since we have not seen a corresponding economic recession. Looking ahead, we believe earnings must advance for equity markets to make meaningful gains. It is early in the third quarter reporting season, but so far the news hasn\u2019t been favorable.<\/p>\n<p><strong>It may take another quarter before corporate earnings accelerate.<\/strong><br \/>\nAt present, consensus expectations are that earnings will decline 3% in the third quarter while revenues rise 3%. Excluding energy, earnings would be up 1% with revenues advancing 4%. Conditions should improve in the fourth quarter, with consensus expectations pointing to a 6% earnings increase&#8230;..<\/p>\n<p>Source: <a href=\"http:\/\/www.nuveen.com\/Commentary\/BobDoll\/WeeklyCommentary.aspx?utm_source=WeeklyCommentary&amp;utm_medium=email&amp;utm_campaign=bobdoll&amp;spMailingID=9704991&amp;spUserID=MTI4MDMxOTQ0MTE5S0&amp;spJobID=1021340194&amp;spReportId=MTAyMTM0MDE5NAS2\">Weekly Investment Commentary from Bob Doll | Nuveen<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>From Bob Doll: Equities may struggle until corporate earnings improve. For the past 18 months, equities have been able to make modest gains despite declining corporate profits. This has largely been due to highly accommodative monetary policy and central banks\u2019 willingness to engage in new easing measures. Additionally, investors have been willing to look past &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Weekly Investment Commentary from Bob Doll | Nuveen&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[57,34],"tags":[455,830,2522],"class_list":["post-14360","post","type-post","status-publish","format-standard","hentry","category-stock-markets","category-us-canada-countries-regions","tag-bob-doll","tag-corporate-earnings","tag-nuveen"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Weekly Investment Commentary from Bob Doll | Nuveen - the patient investor<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Weekly Investment Commentary from Bob Doll | Nuveen - the patient investor\" \/>\n<meta property=\"og:description\" content=\"From Bob Doll: Equities may struggle until corporate earnings improve. For the past 18 months, equities have been able to make modest gains despite declining corporate profits. This has largely been due to highly accommodative monetary policy and central banks\u2019 willingness to engage in new easing measures. Additionally, investors have been willing to look past &hellip; Continue reading &quot;Weekly Investment Commentary from Bob Doll | Nuveen&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/\" \/>\n<meta property=\"og:site_name\" content=\"the patient investor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61572934660810\" \/>\n<meta property=\"article:published_time\" content=\"2016-10-17T23:13:36+00:00\" \/>\n<meta name=\"author\" content=\"ColinTwiggs\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ColinTwiggs\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/\"},\"author\":{\"name\":\"ColinTwiggs\",\"@id\":\"https:\/\/thepatientinvestor.com\/#\/schema\/person\/cb072791ac83e8bae585007c133d54a5\"},\"headline\":\"Weekly Investment Commentary from Bob Doll | Nuveen\",\"datePublished\":\"2016-10-17T23:13:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/\"},\"wordCount\":162,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/thepatientinvestor.com\/#organization\"},\"keywords\":[\"Bob Doll\",\"corporate earnings\",\"Nuveen\"],\"articleSection\":[\"Stock Markets\",\"US &amp; Canada\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/\",\"url\":\"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/\",\"name\":\"Weekly Investment Commentary from Bob Doll | Nuveen - the patient investor\",\"isPartOf\":{\"@id\":\"https:\/\/thepatientinvestor.com\/#website\"},\"datePublished\":\"2016-10-17T23:13:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/thepatientinvestor.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Weekly Investment Commentary from Bob Doll | Nuveen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/thepatientinvestor.com\/#website\",\"url\":\"https:\/\/thepatientinvestor.com\/\",\"name\":\"The Patient Investor\",\"description\":\"Smart. Strategic. Unfiltered. \",\"publisher\":{\"@id\":\"https:\/\/thepatientinvestor.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/thepatientinvestor.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/thepatientinvestor.com\/#organization\",\"name\":\"The Patient Investor Pty Ltd\",\"url\":\"https:\/\/thepatientinvestor.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"width\":250,\"height\":250,\"caption\":\"The Patient Investor Pty Ltd\"},\"image\":{\"@id\":\"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/profile.php?id=61572934660810\",\"https:\/\/www.instagram.com\/colin_thepatientinvestor\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/thepatientinvestor.com\/#\/schema\/person\/cb072791ac83e8bae585007c133d54a5\",\"name\":\"ColinTwiggs\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g\",\"caption\":\"ColinTwiggs\"},\"url\":\"https:\/\/thepatientinvestor.com\/index.php\/author\/colin58s\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Weekly Investment Commentary from Bob Doll | Nuveen - the patient investor","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"Weekly Investment Commentary from Bob Doll | Nuveen - the patient investor","og_description":"From Bob Doll: Equities may struggle until corporate earnings improve. For the past 18 months, equities have been able to make modest gains despite declining corporate profits. This has largely been due to highly accommodative monetary policy and central banks\u2019 willingness to engage in new easing measures. Additionally, investors have been willing to look past &hellip; Continue reading \"Weekly Investment Commentary from Bob Doll | Nuveen\"","og_url":"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/","og_site_name":"the patient investor","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61572934660810","article_published_time":"2016-10-17T23:13:36+00:00","author":"ColinTwiggs","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ColinTwiggs","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/#article","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/"},"author":{"name":"ColinTwiggs","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/cb072791ac83e8bae585007c133d54a5"},"headline":"Weekly Investment Commentary from Bob Doll | Nuveen","datePublished":"2016-10-17T23:13:36+00:00","mainEntityOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/"},"wordCount":162,"commentCount":0,"publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"keywords":["Bob Doll","corporate earnings","Nuveen"],"articleSection":["Stock Markets","US &amp; Canada"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/","url":"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/","name":"Weekly Investment Commentary from Bob Doll | Nuveen - the patient investor","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/#website"},"datePublished":"2016-10-17T23:13:36+00:00","breadcrumb":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/17\/weekly-investment-commentary-from-bob-doll-nuveen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thepatientinvestor.com\/"},{"@type":"ListItem","position":2,"name":"Weekly Investment Commentary from Bob Doll | Nuveen"}]},{"@type":"WebSite","@id":"https:\/\/thepatientinvestor.com\/#website","url":"https:\/\/thepatientinvestor.com\/","name":"The Patient Investor","description":"Smart. Strategic. Unfiltered. ","publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thepatientinvestor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/thepatientinvestor.com\/#organization","name":"The Patient Investor Pty Ltd","url":"https:\/\/thepatientinvestor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","contentUrl":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","width":250,"height":250,"caption":"The Patient Investor Pty Ltd"},"image":{"@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61572934660810","https:\/\/www.instagram.com\/colin_thepatientinvestor"]},{"@type":"Person","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/cb072791ac83e8bae585007c133d54a5","name":"ColinTwiggs","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/876c4d990bb2af282291d5f3ff81533c6deccc0c607846086647ca3272fac0ca?s=96&d=mm&r=g","caption":"ColinTwiggs"},"url":"https:\/\/thepatientinvestor.com\/index.php\/author\/colin58s\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p9tQ4n-3JC","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":15370,"url":"https:\/\/thepatientinvestor.com\/index.php\/2017\/05\/30\/weekly-investment-commentary-from-bob-doll-nuveen-2\/","url_meta":{"origin":14360,"position":0},"title":"Weekly Investment Commentary from Bob Doll | Nuveen","author":"ColinTwiggs","date":"May 30, 2017","format":false,"excerpt":"Key points from Bob Doll's weekly investment summary: We believe U.S. economic growth should rebound in the second quarter and corporate earnings will remain solid. Investors remain uneasy about global macro conditions, but we believe the backdrop remains supportive for equities. We may be seeing a transition in global equity\u2026","rel":"","context":"In &quot;Stock Markets&quot;","block_context":{"text":"Stock Markets","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/stock-markets\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":14196,"url":"https:\/\/thepatientinvestor.com\/index.php\/2016\/09\/19\/bob-doll-equities-appear-more-attractive-than-other-asset-classes-nuveen\/","url_meta":{"origin":14360,"position":1},"title":"Bob Doll: Equities Appear More Attractive than Other Asset Classes | Nuveen","author":"ColinTwiggs","date":"September 19, 2016","format":false,"excerpt":"From Bob Doll's weekly newsletter: The strong patch of summer U.S. economic data may have ended. Following weak Institute for Supply Management readings in previous weeks, August retail sales declined 0.3%. This marks the first pullback since March, and bears watching for a broader downtrend into September..... Corporate earnings expectations\u2026","rel":"","context":"In &quot;Economy&quot;","block_context":{"text":"Economy","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/economy\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":16720,"url":"https:\/\/thepatientinvestor.com\/index.php\/2018\/07\/24\/strong-earnings-results-are-from-revenue-gains-bob-doll\/","url_meta":{"origin":14360,"position":2},"title":"Strong earnings results are from revenue gains | Bob Doll","author":"Colin Twiggs","date":"July 24, 2018","format":"quote","excerpt":"\"Strong earnings results are coming more from revenue gains than bottom-line margins. Since 2010, 90% of positive earnings surprises have come from margins. This quarter, 75% of surprises are from better revenues. This is a healthy sign for future earnings results, and hence for stock prices.\" From Bob Doll at\u2026","rel":"","context":"In &quot;Earnings &amp; Dividends&quot;","block_context":{"text":"Earnings &amp; Dividends","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investing\/earnings-dividends\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":14669,"url":"https:\/\/thepatientinvestor.com\/index.php\/2016\/12\/12\/factors-that-could-derail-equity-markets-bob-doll\/","url_meta":{"origin":14360,"position":3},"title":"Factors that Could Derail Equity Markets | Bob Doll","author":"ColinTwiggs","date":"December 12, 2016","format":false,"excerpt":"From Bob Doll at Nuveen Investments: ....Although we have a generally positive view toward the economy, earnings and equity markets, we think it is worth pointing out some possible risks given how quickly and how far markets have moved higher over the past month. To us, the main risk to\u2026","rel":"","context":"In &quot;Stock Markets&quot;","block_context":{"text":"Stock Markets","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/stock-markets\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":14399,"url":"https:\/\/thepatientinvestor.com\/index.php\/2016\/10\/24\/bob-dolls-bullet-points\/","url_meta":{"origin":14360,"position":4},"title":"Bob Doll&#8217;s bullet points","author":"ColinTwiggs","date":"October 24, 2016","format":false,"excerpt":"From Bob Doll's weekly commentary for Nuveen Investments: Third-quarter earnings started strong. Should this persist, it may mark the end of the earnings recession. It looks likely that Hillary Clinton will win the presidency while the House remains in GOP hands. Equity markets face near-term pressures, but the economic and\u2026","rel":"","context":"In &quot;Stock Markets&quot;","block_context":{"text":"Stock Markets","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/stock-markets\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":16252,"url":"https:\/\/thepatientinvestor.com\/index.php\/2018\/05\/07\/bob-doll-first-quarter-earnings-continue-to-impress\/","url_meta":{"origin":14360,"position":5},"title":"Bob Doll: First quarter earnings continue to impress","author":"Colin Twiggs","date":"May 7, 2018","format":false,"excerpt":"More positive news on earnings from Bob Doll's weekly newsletter: .....2. First quarter earnings results continue to impress, helped by tax cuts. With 85% of companies reporting, earnings are ahead of expectations by an average of 7.3%.1 Earnings-per-share growth is on track for 25%.1 Were it not for the effects\u2026","rel":"","context":"In &quot;Earnings &amp; Dividends&quot;","block_context":{"text":"Earnings &amp; Dividends","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investing\/earnings-dividends\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/14360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/comments?post=14360"}],"version-history":[{"count":0,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/14360\/revisions"}],"wp:attachment":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/media?parent=14360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/categories?post=14360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/tags?post=14360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}